CINCINNATI, May 12, 2011 /PRNewswire/ -- AssureRx Health, Inc., today announced two presentations on the clinical practiceof utilizing its pharmacogenetic test, GeneSightRx®, at the 164th Annual Meeting of the American Psychiatric Association (APA) in Honolulu, May 14-18, 2011. Key activities include a free
Amita Patel, M.D., adult and geriatric psychiatrist at Dayton Psychiatric Associates, and Joel G. Winner, M.D., medical director of AssureRx, will present their scientific and clinical report titled "Using Pharmacogenomic Testing in Clinical Practice" at noon HAST on Sunday, May 15. In addition, Aida Mihajlovic, M.D., assistant professor, Department of Psychiatry, University of Illinois at Chicago and private practice psychiatrist, will present initial findings from a retrospective study of outcomes in outpatients with major depressive disorder (MDD) in a staff model HMO at 10 a.m. HAST on Tuesday, May 17.
A GeneSightRx testing program will also be implemented during the conference for the first 200 physicians who visit AssureRx's booth. The program will provide physicians with the opportunity to experience the simplicity and ease of use in gathering the information necessary to perform the GeneSightRx pharmacogenetic test.
"The presentations and other activities at the APA conference will demonstrate the benefits and simplicity of incorporating the use of GeneSightRx into clinical practice," said John A. Bellano, senior vice president, sales and commercial programs of AssureRx. "Physicians will have the opportunity to hear and experience how, from a simple cheek swab, the GeneSightRx technology can measure and analyze clinically important genetic variants that determine how an individual patient's unique genetic make-up affects his or her ability to tolerate or effectively respond to psychotropic medications."
GeneSightRx is a laboratory developed genetic test that uses cutting edge technology to measure and analyze clinically important genetic variants in psychiatric medicine. The results of the report can help a doctor understand the way a patient's unique genetic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, the FDA approved manufacturer's drug label, and scientifically valid published reports and/or proven pharmacology. Quick turnaround time, combined with a customized report of the patient's genetic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenetics and GeneSightRx, please click here. Be sure to watch the educational video.
About AssureRx Health
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenetics and is dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. The company was founded in 2006 to commercialize industry-leading personalized medicine technology. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators. To learn more about pharmacogenetics and GeneSightRx, please click here.
Contacts:John A. BellanoAssureRx Health, Inc.Tel: (513) 234-0510e-mail: firstname.lastname@example.orgAndreas Marathovouniotis or David Schull Russo PartnersTel: (212) 845-4235 or (212) 845-4271e-mail: email@example.com or firstname.lastname@example.org
SOURCE AssureRx Health, Inc.
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All